RedHill Biopharma Ltd.
RDHL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.01 | 0.01 | 0.00 |
| FCF Yield | -61.27% | -189.42% | -169.09% | -27.14% |
| EV / EBITDA | -1.45 | 0.55 | -5.41 | -4.73 |
| Quality | ||||
| ROIC | 420.64% | 241.02% | -55.17% | -78.81% |
| Gross Margin | 60.31% | 47.03% | 46.06% | 42.39% |
| Cash Conversion Ratio | 1.13 | -1.50 | 0.41 | 0.67 |
| Growth | ||||
| Revenue 3-Year CAGR | -49.32% | -57.61% | -1.34% | 138.88% |
| Free Cash Flow Growth | 73.83% | -21.94% | 54.91% | 36.34% |
| Safety | ||||
| Net Debt / EBITDA | 0.56 | -0.17 | -4.63 | -0.93 |
| Interest Coverage | -265.69 | 34.42 | -1.04 | -4.90 |
| Efficiency | ||||
| Inventory Turnover | 0.87 | 0.79 | 3.03 | 3.34 |
| Cash Conversion Cycle | -319.58 | 300.85 | 297.92 | 161.67 |